Patients with a malignant endometrial adenocarcinoma have been found to benefit from treatments with inhibitors of either LHCGR or the vascular endothelial growth factor receptor 2 (VEGFR2) [49]. This evidence concerns the gene LHCGR and endometrium adenocarcinoma.